ARTICLE | Distillery Therapeutics
Cancer
July 18, 2017 9:03 PM UTC
Cell culture and mouse studies suggest activating PP2A could help treat K-Ras (KRAS)-mutant lung cancer. In five KRAS-mutant human lung cancer cell lines, a previously reported PP2A activator decreased survival compared with no treatment. In three xenograft mouse models of KRAS-mutant lung adenocarcinoma and in one genetic mouse model of KRAS-mutant non-small cell lung cancer (NSCLC), the PP2A activator decreased tumor volume and increased tumor cell apoptosis compared with vehicle. Next steps include optimization of the PP2A activator...
BCIQ Company Profiles
BCIQ Target Profiles